These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27960193)

  • 1. Celecoxib safety revisited.
    Med Lett Drugs Ther; 2016 Dec; 58(1510):159. PubMed ID: 27960193
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.
    Nurmohamed MT
    Nat Rev Rheumatol; 2017 Mar; 13(3):136-138. PubMed ID: 28127041
    [No Abstract]   [Full Text] [Related]  

  • 3. Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial.
    FitzGerald GA
    Circulation; 2017 Jan; 135(2):113-115. PubMed ID: 27840335
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Apr; 107(8):469-470. PubMed ID: 29642790
    [No Abstract]   [Full Text] [Related]  

  • 6. NSAID-associated submucosal fibrous nodules of the small intestine revisited.
    Paton DJW; Kumarasinghe MP
    Pathology; 2020 Oct; 52(6):717-719. PubMed ID: 32771210
    [No Abstract]   [Full Text] [Related]  

  • 7. Celecoxib for the treatment of musculoskeletal arthritis.
    Krasselt M; Baerwald C
    Expert Opin Pharmacother; 2019 Oct; 20(14):1689-1702. PubMed ID: 31339385
    [No Abstract]   [Full Text] [Related]  

  • 8. Celecoxib pathways: pharmacokinetics and pharmacodynamics.
    Gong L; Thorn CF; Bertagnolli MM; Grosser T; Altman RB; Klein TE
    Pharmacogenet Genomics; 2012 Apr; 22(4):310-8. PubMed ID: 22336956
    [No Abstract]   [Full Text] [Related]  

  • 9. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.
    Patrono C; Baigent C
    Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib for the treatment of atherosclerosis.
    Papageorgiou N; Zacharia E; Briasoulis A; Charakida M; Tousoulis D
    Expert Opin Investig Drugs; 2016; 25(5):619-33. PubMed ID: 26940257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 12. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
    Weber AA; Hohlfeld T; Harder S
    Thromb Haemost; 2006 Oct; 96(4):413-6. PubMed ID: 17003916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.
    Warner TD; Mitchell JA
    Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
    Essex MN; Zhang RY; Berger MF; Upadhyay S; Park PW
    Expert Opin Drug Saf; 2013 Jul; 12(4):465-77. PubMed ID: 23506230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced bullous Sweet's syndrome by celecoxib.
    Oh EH; Shin JM; Hong JH; Kim JS; Ro YS; Ko JY
    J Dermatol; 2016 Sep; 43(9):1092-3. PubMed ID: 27060586
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.